Target Name: FDPS
NCBI ID: G2224
Review Report on FDPS Target / Biomarker Content of Review Report on FDPS Target / Biomarker
FDPS
Other Name(s): DMAPP | Farnesyl pyrophosphate synthase | FPP synthase | FPPS_HUMAN | Geranyltranstransferase | KIAA1293 | farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase | FPPS | Geranyl pyrophosphate synthase | FPS | Diprenyltransferase | POROK9 | Farnesyl diphosphate synthase, transcript variant 1 | Farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase | Farnesyl-diphosphate synthase | Geranyl-diphosphate synthase | Farnesyl pyrophosphate synthetase | Farnesylpyrophosphate synthetase | Geranyl pyrophosphate synthetase | Dimethylallyltranstransferase | IPP-dimethylallyltransferase | (2E,6E)-farnesyl diphosphate synthetase | Prenyltransferase | farnesyl diphosphate synthase | Dimethylallyltranstransferase/(2E,6E)-farnesyl diphosphate synthase | FPP synthetase | (2E,6E)-farnesyl diphosphate synthase | Geranyl transferase I | Farnesyl diphosphate synthase | Trans-farnesyl pyrophosphate synthetase | Farnesyl pyrophosphate synthase (isoform a) | FDPS variant 1

Understanding FDPS: A Potential Drug Target for Neurodegenerative Diseases

FDPS (Focal Dendritic Protein-like structure) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The protein has been identified as a potential drug target (DMAPP) due to its unique structure and its ability to interact with various molecules in the brain.

The protein encoded by the FDPS gene is a transmembrane protein that consists of a cytoplasmic tail and a transmembrane domain. The cytoplasmic tail is involved in the protein's stability and localization to the brain, while the transmembrane domain is involved in the protein's interactions with other molecules in the brain.

One of the unique features of FDPS is its ability to interact with various molecules in the brain, including neurotransmitters, ion channels, and signaling proteins. This interaction with other molecules is crucial for the protein's function in the development and progression of neurodegenerative diseases.

For example, research has shown that FDPS interacts with the neurotransmitter dopamine, which is involved in the transmission of signals in the brain. This interaction is important for the development of neurotransmitter-dependent disorders, such as Parkinson's disease.

Additionally, FDPS has been shown to interact with ion channels in the brain, including the N-methyl-D-aspartate (NMDA) channel. This interaction is important for the regulation of neurotransmitter release and the modulation of pain perception.

Another potential mechanism by which FDPS may contribute to neurodegenerative diseases is its role in the regulation of signaling proteins. For example, research has shown that FDPS interacts with the protein p53, which is involved in the regulation of gene expression and the response to stress. This interaction may contribute to the regulation of neurodegenerative diseases, such as Alzheimer's disease.

In conclusion, FDPS is a protein that has been identified as a potential drug target due to its unique structure and its ability to interact with various molecules in the brain. Further research is needed to understand the full function of FDPS in the development and progression of neurodegenerative diseases.

Protein Name: Farnesyl Diphosphate Synthase

Functions: Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate

The "FDPS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FDPS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FDPSP2 | FDPSP4 | FDPSP5 | FDPSP6 | FDPSP7 | FDX1 | FDX2 | FDXACB1 | FDXR | FECH | FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex